According to the site ClinicalTrials.gov, Gilead Sciences has more than doubled the number of participants in its studies for potential COVID-19 treatment remdesivir, reported TheStreet.
Gilead has increased the number of participants in its global, randomized, open-label Phase III test for those afflicted with moderate coronavirus symptoms to 1600 from 600.
The company boosted the number of patients with severe symptoms being tested with the drug to 2400 from 400.
Meanwhile, Gilead expects initial results from the tests in May. Previously, the company said it plans to make 500,000 treatment courses of remdesivir by October and 1 million by year-end.
To read more NewsPoints articles, click here.